Cancer Research Landon Prizes for Basic and Translational Cancer Research  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pastorino, J. G.
Right arrow Articles by Shulga, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pastorino, J. G.
Right arrow Articles by Shulga, N.
[Cancer Research 65, 10545-10554, November 15, 2005]
© 2005 American Association for Cancer Research


Experimental Therapeutics, Molecular Targets, and Chemical Biology

Activation of Glycogen Synthase Kinase 3ß Disrupts the Binding of Hexokinase II to Mitochondria by Phosphorylating Voltage-Dependent Anion Channel and Potentiates Chemotherapy-Induced Cytotoxicity

John G. Pastorino, Jan B. Hoek and Nataly Shulga

Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, Pennsylvania

Requests for reprints: John G. Pastorino, Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Room 272, Jefferson Alumni Hall, Philadelphia, PA 19107. Phone: 215-503-5022; Fax: 215-923-2218; E-mail: John.Pastorino{at}jefferson.edu.

Transformed cells are highly glycolytic and overexpress hexokinase II (HXK II). HXK II is capable of binding to the mitochondria through an interaction with the voltage-dependent anion channel (VDAC), an abundant outer mitochondrial membrane protein. The binding of HXK II to mitochondria has been shown to protect against loss of cell viability. Akt activation inhibits apoptosis partly by promoting the binding of HXK II to the mitochondria, but the mechanism through which Akt accomplishes this has not been characterized. The present report shows that Akt mediates the binding of HXK II to the mitochondria by negatively regulating the activity of glycogen synthase kinase 3ß (GSK3ß). On inhibition of Akt, GSK3ß is activated and phosphorylates VDAC. HXK II is unable to bind VDAC phosphorylated by GSK3ß and dissociates from the mitochondria. Inhibition of Akt potentiates chemotherapy-induced cytotoxicity, an effect that is dependent on GSK3ß activation and its attendant ability to disrupt the binding of HXK II to the mitochondria. Moreover, agents that can force the detachment of HXK II from mitochondria in the absence of Akt inhibition or GSK3ß activation promoted a synergistic increase in cell killing when used in conjunction with chemotherapeutic drugs. Such findings indicate that interference with the binding of HXK II to mitochondria may be a practicable modality by which to potentiate the efficacy of conventional chemotherapeutic agents.




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
S. Abu-Hamad, H. Zaid, A. Israelson, E. Nahon, and V. Shoshan-Barmatz
Hexokinase-I Protection against Apoptotic Cell Death Is Mediated via Interaction with the Voltage-dependent Anion Channel-1: MAPPING THE SITE OF BINDING
J. Biol. Chem., May 9, 2008; 283(19): 13482 - 13490.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
S. J. Clarke, I. Khaliulin, M. Das, J. E. Parker, K. J. Heesom, and A. P. Halestrap
Inhibition of Mitochondrial Permeability Transition Pore Opening by Ischemic Preconditioning Is Probably Mediated by Reduction of Oxidative Stress Rather Than Mitochondrial Protein Phosphorylation
Circ. Res., May 9, 2008; 102(9): 1082 - 1090.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
M. JUHASZOVA, S. WANG, D. B. ZOROV, H. BRADLEY NUSS, M. GLEICHMANN, M. P. MATTSON, and S. J. SOLLOTT
The Identity and Regulation of the Mitochondrial Permeability Transition Pore: Where the Known Meets the Unknown
Ann. N.Y. Acad. Sci., March 1, 2008; 1123(1): 197 - 212.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
L. Sun, S. Shukair, T. J. Naik, F. Moazed, and H. Ardehali
Glucose Phosphorylation and Mitochondrial Binding Are Required for the Protective Effects of Hexokinases I and II
Mol. Cell. Biol., February 1, 2008; 28(3): 1007 - 1017.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
Z. P. Shaik, E. K. Fifer, and G. Nowak
Akt activation improves oxidative phosphorylation in renal proximal tubular cells following nephrotoxicant injury
Am J Physiol Renal Physiol, February 1, 2008; 294(2): F423 - F432.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
C. J. Zuurbier, P. J. M. Keijzers, A. Koeman, H. B. Van Wezel, and M. W. Hollmann
Anesthesia's Effects on Plasma Glucose and Insulin and Cardiac Hexokinase at Similar Hemodynamics and Without Major Surgical Stress in Fed Rats
Anesth. Analg., January 1, 2008; 106(1): 135 - 142.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
W. Kim, J.-H. Yoon, J.-M. Jeong, G.-J. Cheon, T.-S. Lee, J.-I. Yang, S.-C. Park, and H.-S. Lee
Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma
Mol. Cancer Ther., September 1, 2007; 6(9): 2554 - 2562.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
J. Y. Lee, S. J. Yu, Y. G. Park, J. Kim, and J. Sohn
Glycogen Synthase Kinase 3{beta} Phosphorylates p21WAF1/CIP1 for Proteasomal Degradation after UV Irradiation
Mol. Cell. Biol., April 15, 2007; 27(8): 3187 - 3198.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Patenaude, R. G. Deschesnes, J. L.C. Rousseau, E. Petitclerc, J. Lacroix, M.-F. Cote, and R. C.-Gaudreault
New Soft Alkylating Agents with Enhanced Cytotoxicity against Cancer Cells Resistant to Chemotherapeutics and Hypoxia
Cancer Res., March 1, 2007; 67(5): 2306 - 2316.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. Li, Y. Zhou, R. Wang, H. Zhang, Y. Dong, and C. Ip
Selenium sensitizes MCF-7 breast cancer cells to doxorubicin-induced apoptosis through modulation of phospho-Akt and its downstream substrates
Mol. Cancer Ther., March 1, 2007; 6(3): 1031 - 1038.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. Huc, X. Tekpli, J. A. Holme, M. Rissel, A. Solhaug, C. Gardyn, G. Le Moigne, M. Gorria, M.-T. Dimanche-Boitrel, and D. Lagadic-Gossmann
c-Jun NH2-Terminal Kinase-Related Na+/H+ Exchanger Isoform 1 Activation Controls Hexokinase II Expression in Benzo(a)Pyrene-Induced Apoptosis
Cancer Res., February 15, 2007; 67(4): 1696 - 1705.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
G. Kroemer, L. Galluzzi, and C. Brenner
Mitochondrial Membrane Permeabilization in Cell Death
Physiol Rev, January 1, 2007; 87(1): 99 - 163.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.